VERU · Veru Inc.
$2.73
+0.03 (+1.11%)
At close · Aug 14
Going-concern doubt
— flagged Aug 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These uncertainties raise substantial doubt regarding our ability to continue as a going concern for a period of twelve months subsequent to the issuance date of the financial statements included in this report. Certain elements of our operating plan to alleviate the conditions that raise substantial doubt, including but not limited to our ability to secure equity financing or other financing alternatives, are outside of our control and cannot be included in management's evaluation under the requirements of ASC 205-40, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Accordingly, we have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least twelve months subsequent to the issuance date of the financial statements included in this report.”View the 10-Q filed Aug 10, 2026
Market Cap
$46.55M
Shares
17.05M
Veru Inc. Earnings Call Transcripts
Every quarterly earnings call for Veru Inc. (VERU) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▼2.3%
$13.03M
−$14.18M
'22 Q2
22-05-12
▼45.6%
$9.60M
−$22.20M
'22 Q3
22-08-11
▼83.5%
$2.59M
−$41.29M
'22 Q4
22-12-05
▼82.3%
$2.51M
−$38.71M
'23 Q1
23-02-09
▼49.4%
$6.59M
−$33.79M
'23 Q2
23-05-11
▼65.2%
$3.34M
−$12.52M
'23 Q3
23-08-10
▼14.6%
$2.14M
−$8.28M
'24 Q1
24-02-08
▼37.2%
$4.14M
−$10.03M
'24 Q2
24-05-08
▲18.3%
$3.95M
−$10.97M
'24 Q3
24-08-08
▼100%
$
−$7.90M
'25 Q2
25-05-08
LATEST
▼100%
$
−$7.33M
'25 Q3
25-08-12
Conference
Investor event
2026-08-12
Canaccord Genuity's 46th Annual Growth Investors Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-08-10
FY 2026 Q3 Earnings Conference Call
Confident tone
Novo Nordisk clinical supply agreement
GLP-1 weight loss plateau problem
Commercial market opportunity and Medicare reimbursement
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-07-16
2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-05-13
Veru Inc. Q2 FY2026 Earnings Call
Confident tone
Sarcopenic obesity in older patients
Enobosarm Phase 2b Quality trial results
GLP-1 receptor agonist limitations
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-02-26
Oppenheimer 36th Annual Healthcare Life Sciences Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-02-11
Veru Inc. Q4 FY2025 Earnings Call
Confident tone
Novosarm obesity program
Phase 2b PLATO study design
Bone mineral density opportunity
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2025-09-30
Veru Inc. Q4 FY2025 Earnings Call
Confident tone
Enobosarm Phase IIb trial results
FDA regulatory guidance and pathway
PLATEAU Phase IIb clinical trial design
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-08-12
Veru Inc. Q3 FY2025 Earnings Call
Confident tone
Inovasaram Phase 2b QUALITY trial efficacy
Physical function preservation (stair climb)
Maintenance extension / weight regain prevention
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-05-08
Veru Inc. Q2 FY2025 Earnings Call
Confident tone
Enobosarm + GLP-1 obesity program
Physical function (Stair Climb)
Body composition / tissue-selective weight loss
Revenue
$
▼ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-02-13
Veru Inc. Q1 FY2025 Earnings Call
Confident tone
Enobosarm Phase 2b QUALITY study results
Phase 2b extension study
Sabizabulin in atherosclerotic cardiovascular disease
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q3
2024-08-08
Veru Inc. Q3 FY2024 Earnings Call
Revenue
$3.95M
▲ 18.3% YoY Gross margin
33.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-05-08
Veru Inc. Q2 FY2024 Earnings Call
Positive tone
Enobosarm for high-quality weight loss (with GLP-1)
Phase IIb clinical trial design and endpoints
Unmet need around muscle loss on GLP-1 drugs
Revenue
$4.14M
▼ 37.2% YoY Diluted EPS
$-0.70
Gross margin
16.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-02-08
Veru Inc. Q1 FY2024 Earnings Call
Confident tone
Enobosarm for high-quality weight loss with GLP-1
Phase IIb clinical trial design and milestone
GLP-1 muscle loss unmet medical need
Revenue
$2.14M
▼ 14.6% YoY Diluted EPS
$-0.80
Gross margin
53.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q3
2023-08-10
Veru Inc. Q3 FY2023 Earnings Call
Revenue
$3.34M
▼ 65.2% YoY Diluted EPS
$-1.40
Gross margin
36.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-05-11
Veru Inc. Q2 FY2023 Earnings Call
Revenue
$6.59M
▼ 49.4% YoY Diluted EPS
$-4.20
Gross margin
62.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-02-09
Veru Inc. Q1 FY2023 Earnings Call
Revenue
$2.51M
▼ 82.3% YoY Diluted EPS
$-4.80
Gross margin
28.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2022-12-05
Veru Inc. Q4 FY2022 Earnings Call
Revenue
$2.59M*
▼ 83.5% YoY Gross margin
19.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-08-11
Veru Inc. Q3 FY2022 Earnings Call
Revenue
$9.60M
▼ 45.6% YoY Diluted EPS
$-2.80
Gross margin
73.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-05-12
Veru Inc. Q2 FY2022 Earnings Call
Revenue
$13.03M
▼ 2.3% YoY Diluted EPS
$-1.80
Gross margin
85.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-02-09
Veru Inc. Q1 FY2022 Earnings Call
Revenue
$14.14M
▼ 3.3% YoY Diluted EPS
$-0.80
▼ 134.8% YoY Gross margin
83.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2021-12-02
Veru Inc. Q4 FY2021 Earnings Call
Revenue
$15.65M*
▲ 33.2% YoY Gross margin
78.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-08-12
Veru Inc. Q3 FY2021 Earnings Call
Revenue
$17.66M
▲ 71.1% YoY Diluted EPS
$-0.30
Gross margin
78.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-05-12
Veru Inc. Q2 FY2021 Earnings Call
Revenue
$13.34M
▲ 34.2% YoY Diluted EPS
$-0.40
Gross margin
81.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-02-10
Veru Inc. Q1 FY2021 Earnings Call
Revenue
$14.62M
▲ 38.2% YoY Diluted EPS
$2.30
Gross margin
74.1%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2020-12-09
Veru Inc. Q4 FY2020 Earnings Call
Revenue
$11.75M*
▲ 34.6% YoY Gross margin
81.4%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-08-13
Veru Inc. Q3 FY2020 Earnings Call
Revenue
$10.32M
▲ 6.1% YoY Diluted EPS
$-0.50
Gross margin
63.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-05-13
Veru Inc. Q2 FY2020 Earnings Call
Revenue
$9.94M
▲ 42.5% YoY Diluted EPS
$-0.10
Gross margin
74.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-02-12
Veru Inc. Q1 FY2020 Earnings Call
Revenue
$10.58M
▲ 66% YoY Diluted EPS
$-0.50
Gross margin
68.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–28 of 28 earnings calls
Key facts
CIK
863894
CUSIP
92536C202
13F (30d)
61 filings
61 filers
Visit website
Investor relations